Evidence map›Paper›PMID 40071836›Full record

ArticleInternational journal of immunopathology and pharmacology

Impact of tacrolimus on interferon gamma ELISpot assay results for the assessment of T-cell immunity: Proof-of-concept.

Aurélie Truffot, Jules Weinhard, Pauline Dessaud, Patrice Morand, Lionel Rostaing, Françoise Stanke-Labesque, Xavier Fonrose, Raphaële Germi, Thomas Jouve

Abstract read
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aurélie TruffotCNRS, CEA, IRIG IBS, University of Grenoble Alpes, Grenoble, France.ORCID 0000-0002-7991-1733
Jules WeinhardCNRS, Inserm, CHU Grenoble Alpes IAB, University of Grenoble Alpes, Grenoble, France.
Pauline DessaudCNRS, CEA, IRIG IBS, University of Grenoble Alpes, Grenoble, France.
Patrice MorandCNRS, CEA, IRIG IBS, University of Grenoble Alpes, Grenoble, France.
Lionel RostaingCNRS, Inserm, CHU Grenoble Alpes IAB, University of Grenoble Alpes, Grenoble, France.
Françoise Stanke-LabesqueUniv. Grenoble Alpes, Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie, CHU Grenoble Alpes, Grenoble, France.
Xavier FonroseUniv. Grenoble Alpes, Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie, CHU Grenoble Alpes, Grenoble, France.
Raphaële GermiCNRS, CEA, IRIG IBS, University of Grenoble Alpes, Grenoble, France.
Thomas JouveCNRS, Inserm, CHU Grenoble Alpes IAB, University of Grenoble Alpes, Grenoble, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SOT patients require immunosuppressors to avoid graft rejection. Therapeutic drug monitoring is insufficient to find the optimal balance with immunosuppression. The evaluation of cell-mediated immunity by enzyme-linked immunospot (ELISpot) assay enumerating interferon-gamma (IFN-γ) is increasingly use. ELISpot assays are performed on peripheral blood mononuclear cells (PBMC) isolated from blood and brought into contact with specific peptides in an immunosuppressor-free environment. This study aims to determine the

Indexed as

Enzyme-Linked Immunospot AssayImmunity, CellularImmunosuppressive AgentsInterferon-gammaTacrolimusT-LymphocytesHumansLeukocytes, MononuclearMaleProof of Concept StudyImmunosuppressive AgentsInterferon-gammaTacrolimuscell-mediated immunityimmunosupressor diffusion rateinterferon-gamma ELISpot assayperipheral blood mononuclear cellstacrolimus

Identifiers

PMID40071836
PMCPMC11905027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.